BENZIMIDAVIR

Product Name: BENZIMIDAVIR
CAS No.: 176161-24-3
Chemical Name: BENZIMIDAVIR
Synonyms: Maribavir;1263W94;Maribavi;BW 1263W94;GW 257406X;BENZIMIDAVIR;5,6-DICHLORO-2-ISOPROPYLAMINO-1-(-L-RIBOFURANOSYL)-LH-BENZIMIDAZOLE;5,6-DICHLORO-2-(ISOPROPYLAMINO)-1-(BETA-L-RIBOFURANOSYL)-1H-BENZIMIDAZOLE;1H-Benzimidazol-2-amine, 5,6-dichloro-N-(1-methylethyl)-1-β-L-ribofuranosyl-;5,6-Dichloro-N-(1-methylethyl)-1-beta-L-ribofuranosyl-1H-benzimidazol-2-amine
CBNumber: CB6375292
Molecular Formula: C15H19Cl2N3O4
Formula Weight: 376.24
MOL File: 176161-24-3.mol

More

Less

BENZIMIDAVIR Property

Boiling point:: 611.0±65.0 °C(Predicted)
Density: 1.67±0.1 g/cm3 (20 ºC 760 Torr)
storage temp.: 2-8°C(protect from light)
solubility: Soluble in DMSO
form: Powder
pka: 13.20±0.70(Predicted)

More

Less

Hazard and Precautionary Statements (GHS)

Symbol(GHS)

Signal word

Warning

Hazard statements

H302Harmful if swallowed

Precautionary statements

P264Wash hands thoroughly after handling.

P264Wash skin thouroughly after handling.

P270Do not eat, drink or smoke when using this product.

P301+P312IF SWALLOWED: call a POISON CENTER or doctor/physician IF you feel unwell.

P501Dispose of contents/container to..…

More

Less

N-Bromosuccinimide Price

Sigma-Aldrich

Product number: SML2941
Product name: Maribavir
Purity: ≥98% (HPLC)
Packaging: 5MG
Price: $118
Updated: 2024/03/01

Sigma-Aldrich

Product number: SML2941
Product name: Maribavir
Purity: ≥98% (HPLC)
Packaging: 25MG
Price: $476
Updated: 2024/03/01

ChemScene

Product number: CS-2846
Product name: Maribavir
Purity: 99.57%
Packaging: 5mg
Price: $220
Updated: 2021/12/16

ApexBio Technology

Product number: B3517
Product name: Maribavir
Packaging: 5mg
Price: $347
Updated: 2021/12/16

ChemScene

Product number: CS-2846
Product name: Maribavir
Purity: 99.57%
Packaging: 10mg
Price: $350
Updated: 2021/12/16

More

Less

BENZIMIDAVIR Chemical Properties,Usage,Production

Description

Maribavir is an orally bioavailable benzimidazole L-riboside antiviral, with a spectrum of activity essentially limited to human cytomegalovirus (CMV) and Epstein–Barr virus (EBV). It is an inhibitor of the CMV UL97 kinase. As of 2008, maribavir was in phase III clinical trials for prevention of CMV infection in transplant recipients at risk. Earlier phase I and II trials of maribavir showed anti-CMV activity with an acceptable adverse effect profile. Investigational drug code names include 1263W94, BW1263-W94, GW257406X, and VP41263, reflecting changes in ownership during drug development. As of early 2009, the drug was being developed under ‘‘fast track’’ status granted by the US Food and Drug Administration, but the apparent failure of maribar prophylaxis to prevent CMV infection in stem cell transplant recipients in the definitive phase III clinical trial resulted in the sponsor halting ongoing clinical development.

Uses

Treatment of cytomegalovirus infections (antiviral).

Mechanism of action

Maribavir inhibits the CMV UL97 kinase, an enzyme which is required for the normal replication of the virus . In the absence of functioning UL97 kinase, viral replication is severely impaired in vitro, with an abnormal cell culture cytopathic effect characterized by the nuclear aggregation of excess amorphous viral proteins, mainly the tegument protein pp65. Impaired UL97 function appears to cause a defect in viral encapsidation and/or egress of viral particles from the nucleus. In addition, viral DNA synthesis may also be reduced. CMV replication is not completely shut off in the absence of the UL97 kinase; the widely varying maribavir IC50s under different assay conditions suggest that host cells can variably substitute for the normal function of UL97, a factor that may affect the therapeutic potency of maribavir in vivo.

Drug interactions

Since CYP3A4 appears to be the major maribavir-metabolizing enzyme, there are potential drug interactions with CYP3A4 inhibitors, such as azole antifungals, macrolide antibiotics, and HIV protease inhibitors, or CYP3A4 inducers, such as rifampicin or efavirenz. There are insufficient data to assess the clinical significance of this interaction. Phase I clinical trials examined the pharmacokinetics of maribavir in HIV-infected subjects, many of whom were concomitantly using antifungals and protease inhibitors. Overall, the pharmacokinetic data were not significantly different from those of healthy individuals not on these drugs. In healthy adults, oral administration of ketoconazole, a potent CYP3A4 inhibitor, resulted in a 35% decrease in the clearance of maribavir, which is not expected to have adverse consequences because of the low observed toxicity of maribavir. Further studies are required to assess potential impairment of antiviral activity by CYP3A4 inducers. Maribavir may have some inhibitory effect on cytochrome P450 isozymes, CYP2C19 and CYP2D6, as assessed after administration of multiple concurrently administered drug probes, including omeprazole (2C19) and dextromethorphan (2D6).

BENZIMIDAVIR Preparation Products And Raw materials

Raw materials

Preparation Products

More

Less

BENZIMIDAVIR Suppliers

China 117 Germany 1 India 1 United Kingdom 2 United States 16 Global 137

Henan Anky Chemical Technology Co., Ltd.

Tel: 17836913271
Fax: 0374-8348899
Email: 3224305243@qq.com
Country: China
ProdList: 2707
Advantage: 58

Changzhou Bojia Biomedical Technology Co., Ltd.

Tel: 2122619822
Email: czbjpharma@126.com
Country: China
ProdList: 18488
Advantage: 58

Shanghai Shanyuan pharmaceutical technology co., LTD

Tel: 021-31761238 13167072949
Fax: 021-31761238
Email: 3146446224@qq.com
Country: China
ProdList: 1609
Advantage: 55

YICHANG TIANRUI BIOPHARM CO., LTD

Tel: 0717-4065884 18671799682
Email: yctr@renfu.com.cn
Country: China
ProdList: 30
Advantage: 58

Dalian Meilun Biotech Co., Ltd.

Tel: 0411-62910999 13889544652
Email: sales@meilune.com
Country: China
ProdList: 4647
Advantage: 58

Nanjing Vcare PharmaTech Co., Ltd

Tel: 025-58741518 17366379912
Email: sales@vcarepharmatech.com
Country: China
ProdList: 463
Advantage: 58

Shanghai Boyle Chemical Co., Ltd.

Tel
Fax: 86-21-57758967
Email: sales@boylechem.com
Country: China
ProdList: 2923
Advantage: 55

LGM Pharma

Tel: 1-(800)-881-8210
Fax: 615-250-9817
Email: inquiries@lgmpharma.com
Country: United States
ProdList: 2127
Advantage: 70

Nanjing Chemlin Chemical Co., Ltd

Tel: 025-83697070
Fax: +86-25-83453306
Email: info@chemlin.com.cn
Country: China
ProdList: 17938
Advantage: 64

Wuhan Haizheng Industry & Trade Development Co. Ltd

Tel: 027-8866 0053/88660577/88660578
Fax: 027-8899 1911
Country: China
ProdList: 1076
Advantage: 55

176161-24-3, BENZIMIDAVIRRelated Search:

N,N-DIETHYLBENZAMIDE 1-PROPYL-1H-BENZOIMIDAZOL-2-YLAMINE 6-CHLORO-1H-BENZO[D]IMIDAZOL-2-AMINE 1-HYDROXYMETHYLBENZIMIDAZOLE 1H-Benzimidazol-2-amine,5-chloro-1-methyl-(9CI) 5,6-DICHLORO-2-ISOPROPYLAMINOBENZIMIDAZOLE 1,4-ANHYDRO-L-RIBITOL 5,6-DICHLORO-1H-BENZIMIDAZOL-2-AMINE BENZIMIDAVIR

Maribavi

5,6-DICHLORO-2-(ISOPROPYLAMINO)-1-(BETA-L-RIBOFURANOSYL)-1H-BENZIMIDAZOLE

BENZIMIDAVIR

BENZIMIDAVIR, 5,6-DICHLORO-2-（ISOPROPYLAMINO）-1-(β-L-RIBOFURANOSYL)-LH-BENZIMIDAZOLE

5,6-DICHLORO-2-ISOPROPYLAMINO-1-(-L-RIBOFURANOSYL)-LH-BENZIMIDAZOLE

BENZIMIDAVIR: 5,6-DICHLORO-2-(ISOPROPYLAMINO)-1-(SS-L-RIBOFURANOSYL)-LH-BENZIMIDAZOLE

(2S,3S,4R,5S)-2-(5,6-Dichloro-2-(isopropylamino)-1H-benzo[d]-imidazol-1-yl)-5-(hydroxymethyl)tetr

Maribavir

1263W94

5,6-Dichloro-N-(1-methylethyl)-1-beta-L-ribofuranosyl-1H-benzimidazol-2-amine

BW 1263W94

GW 257406X

(2S,3S,4R,5S)-2-(5,6-Dichloro-2-(isopropylamino)-1H-benzo[d]imidazol-1-yl)-5-(hydroxymethyl)tetrahydrofuran-3,4-diol

(2S,3S,4R,5S)-2-(5,6-Dichloro-2-(isopropylamino)-1H-benzo[d]-imidazol-1-yl)-5-(hydroxymethyl)t

1H-Benzimidazol-2-amine, 5,6-dichloro-N-(1-methylethyl)-1-β-L-ribofuranosyl-

176161-24-3

C15H19Cl2N3O4

Inhibitors